Cargando…

Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver

The aim of this study was to analyze dose-volume histogram (DVH) of the remnant liver for postoperative cholangiocarcinoma (CCA) patients, to find toxicity rates, and to confirm efficacy of postoperative radiation therapy (RT). Thirty-two postoperative CCA patients received partial liver resection a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukai, Yuki, Matsuyama, Ryusei, Koike, Izumi, Kumamoto, Takafumi, Kaizu, Hisashi, Homma, Yuki, Takano, Shoko, Sawada, Yu, Sugiura, Madoka, Yabushita, Yasuhiro, Ito, Eiko, Sato, Mizuki, Endo, Itaru, Hata, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709052/
https://www.ncbi.nlm.nih.gov/pubmed/31374045
http://dx.doi.org/10.1097/MD.0000000000016673
_version_ 1783446119466926080
author Mukai, Yuki
Matsuyama, Ryusei
Koike, Izumi
Kumamoto, Takafumi
Kaizu, Hisashi
Homma, Yuki
Takano, Shoko
Sawada, Yu
Sugiura, Madoka
Yabushita, Yasuhiro
Ito, Eiko
Sato, Mizuki
Endo, Itaru
Hata, Masaharu
author_facet Mukai, Yuki
Matsuyama, Ryusei
Koike, Izumi
Kumamoto, Takafumi
Kaizu, Hisashi
Homma, Yuki
Takano, Shoko
Sawada, Yu
Sugiura, Madoka
Yabushita, Yasuhiro
Ito, Eiko
Sato, Mizuki
Endo, Itaru
Hata, Masaharu
author_sort Mukai, Yuki
collection PubMed
description The aim of this study was to analyze dose-volume histogram (DVH) of the remnant liver for postoperative cholangiocarcinoma (CCA) patients, to find toxicity rates, and to confirm efficacy of postoperative radiation therapy (RT). Thirty-two postoperative CCA patients received partial liver resection and postoperative RT with curative intent. The “liver reduction rate” was calculated by contouring liver volume at computed tomography (CT) just before the surgery and at CT for planning the RT. To evaluate late toxicity, the radiation-induced hepatic toxicity (RIHT) was determined by the common terminology criteria for adverse events toxicity grade of bilirubin, aspartate transaminase, alanine transaminase, alkaline phosphatase, and albumin, and was defined from 3 months after RT until liver metastasis was revealed. The radiation-induced liver disease (RILD) was also evaluated. Tumor stages were distributed as follows: I: 1, II: 8, IIIA: 1, IIIB: 6, IIIC: 14, IVA: 2. Median prescribed total dose was 50 Gy. Median follow-up time was 27 months. Two-year overall survival (OS): 72.4%, disease-free survival: 47.7%, local control: 65.3%, and the median survival time was 40 months. The median “liver reduction rate” was 21%. The OS had statistically significant difference in nodal status (P = .032) and “liver reduction rate” >30% (P = .016). In the association between the ≥grade 2 RIHT and DVH, there were significantly differences in V30 and V40 (P = .041, P = .034), respectively. The grade ≥2 RIHT rates differ also significantly by sex (P = .008). Two patients (6.2%) were suspected of RILD. We suggest that RT for remnant liver should be considered the liver V30, V40 to prevent radiation-induced liver dysfunction.
format Online
Article
Text
id pubmed-6709052
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67090522019-10-01 Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver Mukai, Yuki Matsuyama, Ryusei Koike, Izumi Kumamoto, Takafumi Kaizu, Hisashi Homma, Yuki Takano, Shoko Sawada, Yu Sugiura, Madoka Yabushita, Yasuhiro Ito, Eiko Sato, Mizuki Endo, Itaru Hata, Masaharu Medicine (Baltimore) Research Article The aim of this study was to analyze dose-volume histogram (DVH) of the remnant liver for postoperative cholangiocarcinoma (CCA) patients, to find toxicity rates, and to confirm efficacy of postoperative radiation therapy (RT). Thirty-two postoperative CCA patients received partial liver resection and postoperative RT with curative intent. The “liver reduction rate” was calculated by contouring liver volume at computed tomography (CT) just before the surgery and at CT for planning the RT. To evaluate late toxicity, the radiation-induced hepatic toxicity (RIHT) was determined by the common terminology criteria for adverse events toxicity grade of bilirubin, aspartate transaminase, alanine transaminase, alkaline phosphatase, and albumin, and was defined from 3 months after RT until liver metastasis was revealed. The radiation-induced liver disease (RILD) was also evaluated. Tumor stages were distributed as follows: I: 1, II: 8, IIIA: 1, IIIB: 6, IIIC: 14, IVA: 2. Median prescribed total dose was 50 Gy. Median follow-up time was 27 months. Two-year overall survival (OS): 72.4%, disease-free survival: 47.7%, local control: 65.3%, and the median survival time was 40 months. The median “liver reduction rate” was 21%. The OS had statistically significant difference in nodal status (P = .032) and “liver reduction rate” >30% (P = .016). In the association between the ≥grade 2 RIHT and DVH, there were significantly differences in V30 and V40 (P = .041, P = .034), respectively. The grade ≥2 RIHT rates differ also significantly by sex (P = .008). Two patients (6.2%) were suspected of RILD. We suggest that RT for remnant liver should be considered the liver V30, V40 to prevent radiation-induced liver dysfunction. Wolters Kluwer Health 2019-08-02 /pmc/articles/PMC6709052/ /pubmed/31374045 http://dx.doi.org/10.1097/MD.0000000000016673 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Mukai, Yuki
Matsuyama, Ryusei
Koike, Izumi
Kumamoto, Takafumi
Kaizu, Hisashi
Homma, Yuki
Takano, Shoko
Sawada, Yu
Sugiura, Madoka
Yabushita, Yasuhiro
Ito, Eiko
Sato, Mizuki
Endo, Itaru
Hata, Masaharu
Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver
title Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver
title_full Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver
title_fullStr Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver
title_full_unstemmed Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver
title_short Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver
title_sort outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709052/
https://www.ncbi.nlm.nih.gov/pubmed/31374045
http://dx.doi.org/10.1097/MD.0000000000016673
work_keys_str_mv AT mukaiyuki outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT matsuyamaryusei outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT koikeizumi outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT kumamototakafumi outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT kaizuhisashi outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT hommayuki outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT takanoshoko outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT sawadayu outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT sugiuramadoka outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT yabushitayasuhiro outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT itoeiko outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT satomizuki outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT endoitaru outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver
AT hatamasaharu outcomeofpostoperativeradiationtherapyforcholangiocarcinomaandanalysisofdosevolumehistogramofremnantliver